Abstract
Background: Pentoxifylline (PTX) is a drug commonly used in the treatment of intermittent claudication. However, numerous research groups report that PTX also may potentially be used in the anticancer therapy following one of the main trends in the nowadays medicine – combined anticancer therapy.
Scope of Review: The review concentrates on the reports revealing the potential use of PTX in cancer treatment.
Major Conclusion: PTX is described to possess several properties which may be exploited in cancer treatment. The drug reportedly not only has anticancer activity itself, but also increases cancer cells susceptibility to radiation therapy and, additionally, reduces long-term side effects of this therapy. Furthermore, numerous research groups report that PTX may increase the anticancer potential of commonly used anticancer drugs such as cisplatin or doxorubicin as well as reduce side effects of these drugs.
Significance: PTX should be considered as a potential drug in the combined anticancer therapy.
Keywords: Radiosensitization, drug interactions, methylxanthines, anticancer drugs, chemotherapy, drug toxicity.
Graphical Abstract
Current Pharmaceutical Biotechnology
Title:Potential Use of Pentoxifylline in Cancer Therapy
Volume: 19 Issue: 3
Author(s): Grzegorz Golunski*, Anna Woziwodzka and Jacek Piosik*
Affiliation:
- Intercollegiate Faculty of Biotechnology University of Gdansk and Medical University of Gdansk, Abrahama 58, 80-307 Gdansk,Poland
- Intercollegiate Faculty of Biotechnology University of Gdansk and Medical University of Gdansk, Abrahama 58, 80-307 Gdansk,Poland
Keywords: Radiosensitization, drug interactions, methylxanthines, anticancer drugs, chemotherapy, drug toxicity.
Abstract: Background: Pentoxifylline (PTX) is a drug commonly used in the treatment of intermittent claudication. However, numerous research groups report that PTX also may potentially be used in the anticancer therapy following one of the main trends in the nowadays medicine – combined anticancer therapy.
Scope of Review: The review concentrates on the reports revealing the potential use of PTX in cancer treatment.
Major Conclusion: PTX is described to possess several properties which may be exploited in cancer treatment. The drug reportedly not only has anticancer activity itself, but also increases cancer cells susceptibility to radiation therapy and, additionally, reduces long-term side effects of this therapy. Furthermore, numerous research groups report that PTX may increase the anticancer potential of commonly used anticancer drugs such as cisplatin or doxorubicin as well as reduce side effects of these drugs.
Significance: PTX should be considered as a potential drug in the combined anticancer therapy.
Export Options
About this article
Cite this article as:
Golunski Grzegorz *, Woziwodzka Anna and Piosik Jacek *, Potential Use of Pentoxifylline in Cancer Therapy, Current Pharmaceutical Biotechnology 2018; 19 (3) . https://dx.doi.org/10.2174/1389201019666180528084641
DOI https://dx.doi.org/10.2174/1389201019666180528084641 |
Print ISSN 1389-2010 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4316 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Zolpidem Arousing Effect in Persistent Vegetative State Patients: Autonomic, EEG and Behavioral Assessment
Current Pharmaceutical Design Targeting the Lung: Preclinical and Comparative Evaluation of Anticancer Aerosols in Dogs with Naturally Occurring Cancers
Current Cancer Drug Targets Synthesis, Biochemical Evaluation and Rationalisation of the Inhibitory Activity of a Series of 4-Substituted Phenyl Alkyl Triazole-Based Compounds as Potential Inhibitors of 17α-Hydroxylase/17,20-Lyase (P45017α)
Letters in Drug Design & Discovery Overexpression of Nemo-like Kinase Promotes the Proliferation and Invasion of Lung Cancer Cells and Indicates Poor Prognosis
Current Cancer Drug Targets Ethosomes as Vesicles for Effective Transdermal Delivery: From Bench to Clinical Implementation
Current Clinical Pharmacology Recent Advance of Computational Approaches in Genomics and Proteomics
Current Bioinformatics Combination of Microneedles with PLGA Nanoparticles as a Potential Strategy for Topical Drug Delivery
Current Nanoscience Apoptosis Imaging to Monitor Cancer Therapy: The Road to Fast Treatment Evaluation?
Current Pharmaceutical Biotechnology Functional Polymorphism in the <i>MSI1</i> Gene Promoter Confers a Decreased Risk of Lung Cancer in Chinese by Reducing <i>MSI1</i> Expression
Current Genomics Enhancing Nucleic Acid Delivery, Insights from the Cationic Phospholipid Carriers
Current Pharmaceutical Biotechnology Gabapentin for the Treatment of Cancer-Related Pain Syndromes
Reviews on Recent Clinical Trials Targeting DNA Repair Proteins: A Promising Avenue for Cancer Gene Therapy
Current Gene Therapy Leptin: The Prototypic Adipocytokine and its Role in NAFLD
Current Pharmaceutical Design Fluorescent Immortalized Human Adipose Derived Stromal Cells (hASCs-TS/GFP+) for Studying Cell Drug Delivery Mediated by Microvesicles
Anti-Cancer Agents in Medicinal Chemistry Breast Cancer: Understanding Sensitivity and Resistance to Chemotherapy and Targeted Therapies to Aid in Personalised Medicine
Current Cancer Drug Targets Frontier View on Nanotechnological Strategies for Neuro-therapy
Current Drug Metabolism Biochemical Markers of Autoimmune Diseases of the Nervous System
Current Pharmaceutical Design Anti-tumor Efficacy of a Recombinant Human Arginase in Human Hepatocellular Carcinoma
Current Cancer Drug Targets Design, In Silico Modelling, and Functionality Theory of Novel Folate Receptor Targeted Rutin Encapsulated Folic Acid Conjugated Keratin Nanoparticles for Effective Cancer Treatment
Anti-Cancer Agents in Medicinal Chemistry Nutrient-By-Genotype Interactions and Personalized Diet: What Can We Learn From Drosophila and Evolutionary Biology?
Current Pharmacogenomics and Personalized Medicine